Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors

DISEASE CHARACTERISTICS: * Histologically confirmed malignant solid tumor that did not respond to or relapsed after standard first-line chemotherapy or other antineoplastic therapy (if the standard therapy for the tumor is generally recognized to be beneficial) * Must have been initially diagnosed with malignancy prior to 25 years of age * Radiographic, nuclear image, or biopsy confirmation of disease within the past 4 weeks * Meets one of the following criteria: * Phase I: Relapsed/refractory malignant solid tumor (excluding CNS tumors) * Patients with recurrent or metastatic disease that was completely resected just prior to study entry are eligible * Phase II: Patients are stratified according to one of the following diagnoses: * Stratum A: Relapsed sarcoma (rhabdomyosarcoma, osteosarcoma, or Ewing sarcoma) * Stratum B: Other relapsed solid tumors, including any of the following: * Other soft tissue sarcomas * Kidney tumors * Lymphoma * CNS tumors\* * Other solid tumors (neuroblastoma, gonadal and germ cell tumors, liver tumors, or miscellaneous tumors) * Stratum C: Newly diagnosed, poor-risk metastatic sarcoma consisting of unresectable pulmonary metastases (≥ 6 nodules) and/or disease involving multiple bones or other organs NOTE: \*Patients with recurrent primary CNS tumors are eligible for the phase II portion of this study provided there are no significant intratumoral bleeding toxicities seen in either COG p…